



# Core Project R03OD030604



## Details

| Projects        | Name   | Award        | Publications   | Repositories   | Analytics    |
|-----------------|--|--------------|----------------|----------------|--------------|
| 1R03OD030604-01 | Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing | \$297,000.00 | 8 publications | 0 repositories | 0 properties |



## Publications

Published works associated with this project.

| ID  | Title   | Authors           | R<br>C<br>R | SJ<br>R  | Cita<br>tion<br>s | Cit./<br>yea<br>r | Journal                    | Publ<br>ishe<br>d | Updat<br>ed    |
|---|---|-------------------|-------------|----------|-------------------|-------------------|----------------------------|-------------------|----------------|
| <a href="#">35337371</a><br><a href="#">DOI</a> | Considerations and challenges for sex-aware drug repurposing. | Jennifer L Fisher | 1.<br>57    | 2.0<br>3 | 9                 | 4.5               | Biology of Sex Differences | 2,02<br>2         | Sep 1,<br>2024 |

|   |  |  |   |           |   |   |                         |       |                                       |
|---|--|--|---|-----------|---|---|-------------------------|-------|---------------------------------------|
|   |  | ...4<br>more...<br>Brittany<br>N<br>Lasseign<br>e                        |   |           |   |   |                         |       | (3<br>weeks<br>ago)                   |
| <a href="#">37533331</a><br><a href="#">DOI</a> | Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease... | Avery S<br>Williams<br>...2<br>more...<br>Brittany<br>N<br>Lasseign<br>e | 0 | 0         | 3 | 3 | Cancer Rep<br>(Hoboken) | 2,023 | Sep 1,<br>2024<br>(3<br>weeks<br>ago) |
| <a href="#">37217845</a><br><a href="#">DOI</a> | Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and... | Elizabeth<br>J Wilk<br>...9<br>more...<br>Brittany<br>N<br>Lasseign<br>e | 0 | 1.4<br>46 | 1 | 1 | Molecular<br>Medicine   | 2,023 | Sep 1,<br>2024<br>(3<br>weeks<br>ago) |
| <a href="#">38531616</a><br><a href="#">DOI</a> | Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposi... | Jennifer L<br>Fisher<br>...7<br>more...<br>Brittany                      | 0 | 0.7<br>89 | 0 | 0 | FEBS Open Bio           | 2,024 | Sep 1,<br>2024<br>(3<br>weeks<br>ago) |

|   |  |   |   |       |   |   |                               |       |                           |
|---|--|---|---|-------|---|---|-------------------------------|-------|---------------------------|
|   |  | N<br>Lasseign<br>e  |   |       |   |   |                               |       |                           |
| <a href="#">38167211</a><br><a href="#">DOI</a> | Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ... | Jennifer L Fisher<br>...2 more...<br>Brittany N Lasseign<br>e | 0 | 0.71  | 0 | 0 | BMC pharmacology & toxicology | 2,024 | Sep 1, 2024 (3 weeks ago) |
| <a href="#">37362157</a><br><a href="#">DOI</a> | Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ... | Jennifer L Fisher<br>...2 more...<br>Brittany N Lasseign<br>e | 0 | 0     | 0 | 0 | bioRxiv                       | 2,023 | Sep 1, 2024 (3 weeks ago) |
| <a href="#">36602970</a><br><a href="#">DOI</a> | Ten simple rules for using public biological data for your research.                                 | Vishal H Oza<br>...9 more...<br>Brittany N Lasseign<br>e      | 0 | 1.652 | 2 | 2 | PLoS Computational Biology    | 2,023 | Sep 11, 2024 (1 week ago) |

|   |  |  |   |   |   |   |         |       |                              |
|---|--|--|---|---|---|---|---------|-------|------------------------------|
| <a href="#">37090499</a><br><a href="#">DOI</a> | Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease... | Avery S Williams<br>...2 more...<br>Brittany N Lasseigne | 0 | 0 | 0 | 0 | bioRxiv | 2,023 | Sep 1, 2024<br>(3 weeks ago) |
|---|--|--|---|---|---|---|---------|-------|------------------------------|

Notes


RCR [Relative Citation Ratio](#)

SJR [Scimago Journal Rank](#)

Software repositories associated with this project.

## Cumulative Publications

Total: 8



## Notes

**Repository** For storing, tracking changes to, and collaborating on a piece of software.

PR "Pull request", a draft change (new feature, bug fix etc.) to a repo.

Closed/Open      Resolved/unresolved.

**Avg Issue/PR** Average time issues/pull requests stay open for before being closed.

Only the `main` /default branch is considered for metrics like # of commits.

# of dependencies is totaled from all manifests in repo, direct and transitive, e.g. `package.json` + `package-lock.json`.



## Analytics

Traffic metrics of websites associated with this project.

# Notes

- Active Users        [Distinct users who visited the website](#) .
- New Users         [Users who visited the website for the first time](#) .
- Engaged Sessions   [Visits that had significant interaction](#) .

"Top" metrics are measured by number of engaged sessions.